TNF Pharmaceuticals Inc (Nasdaq: TNFA), a clinical stage biopharmaceutical company developing novel oral therapies for autoimmune and inflammatory conditions, on Wednesday announced positive clinical data supporting the expansion of its Phase 2b study for isomyosamine, its novel TNF-alpha (TNF-α) inhibitor drug, into multiple indications.
The company has successfully completed an FDA-recommended safety study, which showed favorable results over 13 weeks at all dose levels.
TNFA plans to initiate a Phase 2b clinical trial in early 2025 to assess the efficacy of isomyosamine in treating sarcopenia, a market expected to reach USD4.02bn by 2029. Additionally, the company will launch a study to evaluate isomyosamine as a treatment for GLP-1-induced sarcopenia and frailty in patients using GLP-1 agonists like Wegovy or Ozempic, targeting a rapidly growing USD105bn market by 2029.
Isomyosamine, a novel small molecule, modulates inflammatory cytokines including TNF-α, which plays a key role in aging and various age-related diseases. The TNF inhibitor market alone is projected to reach USD47.3bn by 2029.
Sanofi and J&J discontinue phase 3 study of E. coli vaccine candidate
OnCusp Therapeutics' CUSP06 receives US FDA Fast Track Designation
MimiVax reports positive interim analysis of SurVaxM Phase 2b clinical trial
Akeso enrols first patient in cadonilimab Phase 3 clinical trial
NKGen Biotech receives US FDA Fast Track designation for troculeucel in Alzheimer's treatment
Neuphoria Therapeutics to receive USD15m milestone payment from Merck
TriNetX and Fujitsu form joint venture to enhance clinical research in Japan
Royalty Pharma to invest up to USD250m in Biogen's lupus treatment
Lundbeck receives FDA Fast Track designation for amlenetug in multiple system atrophy
Lytix Biopharma secures US patent allowance for LTX-315 clinical programme
GenSight Biologics reports positive five-year resultsfor LUMEVOQ gene therapy
IXICO's AI platform validated in Huntington's Disease research
ILIKOS Consulting partners with Jordan Center for Pharmaceutical Research
Spinogenix reveals topline results from Phase 2 study in Fragile X syndrome
Moleculin's Phase 3 R/R AML pivotal trial receives first European country recruitment approval